RenovoRx, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
Mailing Address 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
Phone 408-800-2649
Fiscal Year End 1231
EIN 271448452
Financial Overview
FY2024
$8.12M
Total Assets
$7.15M
Cash & Equivalents
$-0.40
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | December 22, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 17, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
Material Events
8-K Financial Distress January 2, 2026
High Impact
- RenovoRx, Inc. received a formal warning from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
- The company's common stock traded below $1.00 for 32 consecutive business days, putting its Nasdaq listing at risk.
Insider Trading
BUY 2 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.